Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT

Area of Science:

• Cardiovascular Physiology
• Sleep Medicine
• Pharmacology

Background:

• Restless Legs Syndrome (RLS) is associated with periodic limb movements (PLMs) during sleep.
• Nocturnal blood pressure (BP) elevations can occur in conjunction with PLMs.
• The impact of RLS treatments on these BP fluctuations is not fully understood.

Purpose of the Study:

• To investigate the efficacy of rotigotine patch in reducing periodic limb movement (PLM)-associated nocturnal systolic blood pressure (SBP) elevations in patients with moderate to severe RLS.
• To evaluate the effects of rotigotine on other BP parameters, PLM index, and sleep arousal index.

Main Methods:

• A double-blind, placebo-controlled, interventional trial randomized patients with moderate to severe RLS to rotigotine (1-3 mg/24 h) or placebo.
• Continuous beat-to-beat blood pressure (BP) was monitored during polysomnography at baseline and after 4 weeks.
• Primary outcome: change in the number of PLM-associated SBP elevations; secondary outcomes included total SBP/DBP elevations, PLM index (PLMI), and PLM in sleep arousal index (PLMSAI).

Main Results:

• Rotigotine significantly reduced PLM-associated SBP elevations compared to placebo (p < 0.0001).
• Significant reductions were also observed with rotigotine for total SBP elevations, PLM-associated DBP elevations, total DBP elevations, PLMI, and PLMSAI.
• Common adverse events included nausea, headache, nasopharyngitis, and fatigue, with similar rates for headache and nasopharyngitis between groups.

Conclusions:

• Rotigotine at an optimal dose effectively reduces nocturnal blood pressure elevations associated with periodic limb movements in RLS patients.
• The study provides Class I evidence supporting rotigotine's efficacy in this context.
• Further research is needed to determine if these BP reductions translate to modified cardiovascular risk.